Nkarta, Inc. (NKTX)
NASDAQ:NKTX
Want to see NKTX full AI Analyst Report?
NKTX Stock Chart & Stats
$3.47
-$0.05(-2.07%)
At close: 4:00 PM EST
$3.47
-$0.05(-2.07%)
Day’s Range― - ―
52-Week Range$1.63 - $3.65
Previous CloseN/A
Volume369.36K
Average Volume (3M)983.43K
Market Cap
$236.10M
Enterprise Value$280.17M
Total Cash (Recent Filing)$230.43M
Total Debt (Recent Filing)$75.00M
Price to Earnings (P/E)―
Beta1.55
Next Earnings
Aug 06, 2026EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.34
Shares Outstanding71,545,360
10 Day Avg. Volume644,627
30 Day Avg. Volume983,433
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)0.44
Price to Sales (P/S)0.00
P/FCF Ratio-1.52
Enterprise Value/Market Cap1.19
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-119.73
Enterprise Value/Ebitda-2.76
Forecast
1Y Price Target
$11.80Price Target Upside240.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.45
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Allogeneic Off-the-shelf NK Cell PlatformNkarta's focus on allogeneic, off-the-shelf NK cell therapies is a durable strategic advantage versus autologous approaches. Scalable manufacturing and off-the-shelf delivery can reduce per-patient complexity, support broader commercial rollouts, and address larger patient populations once clinical proof and approvals are achieved.
Moderate Leverage And Relative Balance Sheet StrengthDebt levels around a 0.26 debt-to-equity ratio indicate the company is not overly debt-funded, preserving financial flexibility. For a clinical-stage biotech, moderate leverage reduces near-term solvency risk and allows management to pursue R&D programs without heavy interest-driven cash drain.
Structured Access To Capital Via ATM FacilityThe $100M at-the-market (ATM) facility provides a structural mechanism to raise opportunistic equity over time, extending runway and allowing smaller, timed raises instead of one large dilutive event. This flexibility helps fund ongoing clinical development and preserves optionality in capital markets execution.
Bears Say
Pre-commercial With No Product RevenueNkarta is a pre-revenue biotech with no product sales, leaving the company dependent on collaborations and financings to fund operations. Until product approvals and commercialization occur, revenue visibility is limited and the business model lacks recurring commercial cash flows to offset R&D spend.
Persistent Negative Operating And Free Cash FlowSustained negative operating and free cash flow of roughly -$87M to -$88M TTM implies continued cash burn to advance trials. This structural cash consumption requires recurring external financing, raising dilution risk and potentially constraining investment pace if capital markets access tightens.
Erosion Of Shareholder Equity Over TimeThe decline in shareholders' equity across reporting periods reflects cumulative losses and past financing patterns. Persistent erosion undermines capitalization, signals ongoing funding needs, and increases the likelihood of future dilutive financings or less favorable funding terms, affecting long-term shareholder value.
Nkarta News
NKTX FAQ
What was Nkarta, Inc.’s price range in the past 12 months?
Nkarta, Inc. lowest stock price was $1.63 and its highest was $3.65 in the past 12 months.
What is Nkarta, Inc.’s market cap?
Nkarta, Inc.’s market cap is $236.10M.
When is Nkarta, Inc.’s upcoming earnings report date?
Nkarta, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 67 days.
How were Nkarta, Inc.’s earnings last quarter?
Nkarta, Inc. released its earnings results on May 12, 2026. The company reported -$0.37 earnings per share for the quarter, missing the consensus estimate of -$0.354 by -$0.016.
Is Nkarta, Inc. overvalued?
According to Wall Street analysts Nkarta, Inc.’s price is currently Undervalued.
Does Nkarta, Inc. pay dividends?
Nkarta, Inc. does not currently pay dividends.
What is Nkarta, Inc.’s EPS estimate?
Nkarta, Inc.’s EPS estimate is -0.36.
How many shares outstanding does Nkarta, Inc. have?
Nkarta, Inc. has 71,545,360 shares outstanding.
What happened to Nkarta, Inc.’s price movement after its last earnings report?
Nkarta, Inc. reported an EPS of -$0.37 in its last earnings report, missing expectations of -$0.354. Following the earnings report the stock price went down -6.707%.
Which hedge fund is a major shareholder of Nkarta, Inc.?
Currently, no hedge funds are holding shares in NKTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nkarta Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.80 (240.06% Upside)
$11.80 (240.06% Upside)
Blogger Sentiment
Bullish
NKTX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 846.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days <0.1%
Last 30 Days ▲ 7.4%
Last 30 Days ▲ 7.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
79.55%
12-Months-Change
Fundamentals
Return on Equity
-30.90%
Trailing 12-Months
Asset Growth
-20.94%
Trailing 12-Months
Company Description
Nkarta, Inc.
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
NKTX Stock 12 Month Forecast
Average Price Target
$11.80
▲(240.06% Upside)
Technical Analysis
Ownership Overview
20.64% Insiders
7.56% Mutual Funds
48.74% Other Institutional Investors
16.60% Public Companies and
Individual Investors